Closed · opens Mon 9:30 AM ET
The Marked Chart Wire · Health
Takeda
Takeda reported that its experimental treatment arcotatug tavatecan achieved both main objectives in a late-stage study for advanced stomach cancer. The therapy demonstrated meaningful gains in patient longevity and time before the disease worsened.
CRISPR Therapeutics
CRISPR Therapeutics' pipeline candidate CTX310 is viewed as having a larger market opportunity than its approved product Casgevy.
Nubeqa
Orion Corporation stated that adding Nubeqa to standard care significantly lowered the chance of disease spread or mortality in high-risk patients.
Lung Cancer
Amgen reported that adding its medication to AstraZeneca’s immunotherapy reduced the chance of death by 58 percent for individuals with advanced lung tumors.
Cancer Vaccine
The two companies disclosed late-stage clinical findings for their mRNA therapy, intismeran autogene, after an information leak occurred.
AbbVie
The FDA approved an injectable version of AbbVie's Skyrizi to treat moderate to severe Crohn's disease.
Novartis
Novartis said its drug remibrutinib met primary endpoints in phase 3 trials for rhabdomyosarcoma. The treatment cut relapse rates by 35 percent compared with a rival therapy, and the company plans to seek global approval.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.